8-K/A: Aditxt Amends Filing to Include Appili Therapeutics Financials Amidst Acquisition Delays

Aditxt, Inc. files an amendment to its previous report to include the financial statements of Appili Therapeutics as the acquisition faces continued delays and waivers.

Summary

• Aditxt, Inc. has filed an amendment to its previous report on Form 8-K/A to include the unaudited condensed consolidated financial statements of Appili Therapeutics, Inc. as of and for the nine months ended December 31, 2024 and 2023, and the pro forma consolidated financial information as of and for the twelve months ended December 31, 2024.
• This amendment, the fourth, relates to the Arrangement Agreement between Aditxt, its subsidiary Adivir, Inc., and Appili Therapeutics, Inc., where Adivir is set to acquire all outstanding Class A common shares of Appili.
• The original agreement has been amended multiple times, primarily to extend deadlines for completing the acquisition and related financing.
• The latest amendment includes waivers to termination rights, with Adivir making payments to Appili for these extensions, including a $115,000 waiver fee paid on November 12, 2024, and subsequent payments of $250,000 each in December 2024 and January 2025, and two payments of $125,000 in February and March 2025.
• The pro forma financial information is presented for informational purposes only and does not represent the actual results if the entities were combined or project future results.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the acquisition is progressing, the repeated delays, need for additional financing, and Appili's financial losses raise concerns.

Positives

• Aditxt is moving forward with the acquisition of Appili Therapeutics.
• The inclusion of Appili's financial statements provides more transparency for investors.
• The waivers and amendments suggest a continued commitment from all parties to complete the transaction.

Negatives

• The repeated amendments and waivers indicate potential challenges in completing the acquisition.
• The pro forma financial information does not guarantee future results and is for informational purposes only.
• Appili reported a loss of $2,852,742 for the nine months ended December 31, 2024, and has an accumulated deficit of $71,945,858.

Risks

• The acquisition is contingent on Aditxt raising at least US$20 million in financing.
• Appili's ability to continue as a going concern is dependent on successfully closing the transaction with Aditxt or raising additional financing.
• There is a risk that the acquisition may not be completed, potentially impacting both Aditxt and Appili.

Future Outlook

The closing of the Appili acquisition is expected to occur in the first quarter of calendar 2025, subject to the satisfaction of all closing conditions, including Aditxt raising at least US$20 million in financing.

Industry Context

The biopharmaceutical industry is characterized by high risk and high reward, with companies often relying on acquisitions and partnerships to expand their pipelines and access new technologies. This announcement reflects this trend, with Aditxt seeking to strengthen its position through the acquisition of Appili Therapeutics.

Comparison to Industry Standards

• It is difficult to compare Appili's results to industry standards without knowing the specific therapeutic areas and stage of development of its pipeline.
• However, early-stage biopharmaceutical companies often operate at a loss as they invest heavily in research and development.
• The pro forma financial information provides a glimpse into the potential financial impact of the acquisition on Aditxt, but it is important to note that these are just estimates and may not reflect actual results.

Stakeholder Impact

• Shareholders of Appili will receive Aditxt stock and cash upon completion of the acquisition.
• Employees of both companies may experience changes as a result of the acquisition.
• Customers and partners of both companies may see changes in product offerings and business relationships.

Next Steps

• Aditxt needs to secure the required financing of US$20 million.
• Appili needs to continue operating and managing its finances until the acquisition is complete.
• Both companies need to work towards satisfying the remaining closing conditions.

Key Dates

Keywords

Aditxt, Appili Therapeutics, Adivir, Acquisition, Arrangement Agreement, Financial Statements, Pro Forma, Amendment, Waiver, Financing